EN
 
EN

Mylan Worldwide

Close

Please select one of our websites from the list below.

  1. Africa

    1. South Africa
      1. English
  2. Americas

    1. Brazil
      1. Português brasileiro
    2. Canada
      1. English
      2. Français
    3. United States
      1. English
  3. Asia

    1. India
      1. English
    2. Japan
      1. 日本語
  4. Europe

    1. Austria
      1. Deutsch
    2. Belgium
      1. Français
      2. Nederlands
    3. Bulgaria
      1. България
    4. Czech Republic
      1. Čeština
    5. Denmark
      1. Dansk
    6. Finland
      1. Suomi
    7. France
      1. Français
    8. Germany
      1. Deutsch
    9. Greece
      1. Ελληνικά
    10. Hungary
      1. Magyar
    11. Ireland
      1. English
    12. Italy
      1. Italiano
    13. Netherlands
      1. Nederlands
    14. Norway
      1. Norsk
    15. Poland
      1. Polski
    16. Portugal
      1. Português
    17. Romania
      1. Română
    18. Serbia
      1. Serbian Latin
    19. Slovakia
      1. Slovenský
    20. Slovenia
      1. Slovenian
    21. Spain
      1. Español
    22. Sweden
      1. Svensk
    23. Switzerland
      1. Deutsch
      2. English
    24. United Kingdom
      1. English
  5. Pacific

    1. Australia
      1. English
    2. New Zealand
      1. English

Mylan also is proud to do business in these locations.

  1. Morocco
  2. Luxembourg
  3. Taiwan
  1. China
  2. Singapore
Jan 1, 2014

Answers for an Epidemic

Answers for an Epidemic



See how an innovative, heat-stable antiretroviral (ARV) is changing HIV/AIDS treatment.

In developing countries where electricity is unpredictable, refrigeration tends to be scarce. HIV/AIDS, on the other hand, may be all too common. For the millions living with HIV/AIDS in places such as sub-Saharan Africa, a lack of refrigeration once meant a lack of access to antiretroviral medicines.

This is because Ritonavir, one of the three different medicines required for one important HIV/AIDS treatment regimen, breaks down if not refrigerated. Ritonavir is used to enhance the performance of protease inhibitors, such as Lopinavir, another medicine used in HIV/AIDS treatment regimens.
The question we asked was: “Can we make an affordable, heat-stable version of Ritonavir accessible in sufficient quantities to people in the developing world?” The answer was: “Yes”.

We developed a high-quality generic Ritonavir that is heat-stable and approved by the World Health Organization as part of a second-line treatment option for people who have developed a resistance to first-line HIV/AIDS treatment. Today, the medicine is available in sub-Saharan Africa, Latin and Central America, the Caribbean and Southeast Asia.
Our efforts allowed us to increase access to this high-quality medicine and at the same time fulfil a commitment we made to former President Bill Clinton to lower the price of second-line treatment for HIV/AIDS in developing countries.



Last Updated  2015/06/10